Bendamustine Hydrochloride API

Name	Bendamustine hydrochloride
Chinese name	盐酸苯达莫司汀
Cas Number	3543-75-7
Source	Europe
Qualifications	USDMF/-/-/-/-

Bendamustine hydrochloride was developed by Cephalon, USA, and was approved for marketing by the US Food and Drug Administration in March 2008. Bendamustine hydrochloride is a bifunctional alkylating agent with dual action mechanisms of alkylating agent and purine analogs. Its unique heterocyclic structure gives it unique anti-tumor activity. Both the FDA and European EMA have approved bendamustine for the treatment of indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine hydrochloride, as a new generation of anti-cancer drugs, has obvious therapeutic effects on various cancers. Clinical application shows that it has a definite effect on the treatment of indolent B-cell non-Hodgkin's lymphoma, significantly reduces the recurrence rate and mortality, and has fewer adverse reactions than similar varieties and high safety. With more than ten years of experience worldwide, it has been recommended by multinational guidelines and Chinese lymphoma treatment guidelines as a standard solution for multiple subtypes of B-cell lymphoma. According to data from Meinenet, the global sales of bendamustine hydrochloride in 2018 have exceeded US$600 million.

Hot Tags: bendamustine hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Cinacalcet Hydrochloride API, Ranolazine API, Tavaborol API, Dapoxetine API, Solinasine Succinate API, Vardenafil API

• Previous: Brimonidine Tartrate API
• Next: Titagliptin Hydrobromide API